OrthoPediatrics (KIDS) to Announce Quarterly Earnings on Tuesday

OrthoPediatrics (NASDAQ:KIDS) is expected to post its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect OrthoPediatrics to announce earnings of ($0.31) per share and revenue of $68.21 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Thursday, April 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.04. OrthoPediatrics had a negative return on equity of 7.01% and a negative net margin of 16.31%.The business had revenue of $59.36 million during the quarter, compared to analyst estimates of $58.28 million. On average, analysts expect OrthoPediatrics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

OrthoPediatrics Price Performance

NASDAQ KIDS traded up $0.07 on Tuesday, reaching $19.89. 24,716 shares of the company’s stock traded hands, compared to its average volume of 157,204. OrthoPediatrics has a 12 month low of $14.42 and a 12 month high of $22.89. The company has a debt-to-equity ratio of 0.29, a current ratio of 5.21 and a quick ratio of 2.37. The stock has a 50-day simple moving average of $18.84 and a 200 day simple moving average of $17.75. The stock has a market cap of $510.78 million, a PE ratio of -11.84 and a beta of 0.99.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on KIDS shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OrthoPediatrics in a research note on Friday, July 17th. TD Cowen reissued a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Truist Financial upped their price target on shares of OrthoPediatrics from $17.00 to $20.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Canaccord Genuity Group set a $25.00 price objective on OrthoPediatrics in a research note on Friday, April 24th. Finally, BTIG Research reissued a “buy” rating and issued a $24.00 target price on shares of OrthoPediatrics in a research note on Friday, May 1st. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, OrthoPediatrics has an average rating of “Moderate Buy” and a consensus target price of $24.78.

Hedge Funds Weigh In On OrthoPediatrics

Hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. boosted its holdings in shares of OrthoPediatrics by 433.1% during the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after purchasing an additional 1,139 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in OrthoPediatrics by 5,226.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after purchasing an additional 2,561 shares during the period. Caption Management LLC purchased a new position in OrthoPediatrics during the 3rd quarter valued at about $54,000. BNP Paribas Financial Markets raised its position in OrthoPediatrics by 60.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after purchasing an additional 1,235 shares during the last quarter. Finally, State of Wyoming raised its position in OrthoPediatrics by 189.7% during the 4th quarter. State of Wyoming now owns 6,822 shares of the company’s stock valued at $121,000 after purchasing an additional 4,467 shares during the last quarter. 69.05% of the stock is owned by institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.